What is Zacks Research’s Estimate for Soligenix Q3 Earnings?

Posted by George Bondi on Aug 18th, 2026

Soligenix Inc. (NASDAQ:SNGX – Free Report) – Equities research analysts at Zacks Research lifted their Q3 2026 earnings per share (EPS) estimates for shares of Soligenix in a research note issued to investors on Wednesday, August 12th. Zacks Research analyst D. Bautz now expects that the biopharmaceutical company will earn ($0.12) per share for the quarter, up from their previous forecast of ($0.21). The consensus estimate for Soligenix’s current full-year earnings is ($0.55) per share. Zacks Research also issued estimates for Soligenix’s Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.40) EPS and FY2028 earnings at ($0.38) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Soligenix currently has an average rating of “Sell”.

Check Out Our Latest Report on SNGX

Soligenix Stock Performance

Shares of SNGX opened at $0.38 on Monday. The stock has a market capitalization of $5.65 million, a PE ratio of -0.39 and a beta of 1.93. The company’s fifty day moving average is $0.39 and its 200 day moving average is $0.76. Soligenix has a fifty-two week low of $0.28 and a fifty-two week high of $6.23.

Soligenix (NASDAQ:SNGX – Get Free Report) last posted its earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04.

Institutional Trading of Soligenix

Hedge funds and other institutional investors have recently bought and sold shares of the stock. StoneX Group Inc. bought a new stake in Soligenix in the fourth quarter worth $50,000. Jane Street Group LLC bought a new position in Soligenix during the fourth quarter valued at $51,000. Geode Capital Management LLC increased its position in Soligenix by 88.8% during the fourth quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 37,811 shares during the last quarter. Armistice Capital LLC purchased a new stake in shares of Soligenix in the third quarter valued at $821,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Soligenix in the third quarter valued at $102,000. Hedge funds and other institutional investors own 3.60% of the company’s stock.

Soligenix Company Profile

(Get Free Report)

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.